{"denoms":[{"counts":[{"groupId":"BG000","value":"97"}],"units":"Participants"}],"groups":[{"description":"Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.","id":"BG000","title":"Rituximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.5","value":"56.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"40"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"The safety population included all participants who received any active dose of rituximab."}